We are live on ! Find out more
CTSO icon

Cytosorbents Corp

72 hedge funds and large institutions have $56.3M invested in Cytosorbents Corp in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 22

0.44% less ownership

Funds ownership: 26.84%26.41% (-0.44%)

6% less funds holding

Funds holding: 7772 (-5)

13% less capital invested

Capital invested by funds: $64.8M → $56.3M (-$8.52M)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $19K

Holders
72
Holders Change
-5
Holders Change %
-6.49%
% of All Funds
1.56%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
25
Reduced
22
Closed
10
Calls
Puts
$19K
Net Calls
-$19K
Net Calls Change
-$50K

CTSO Hedge Fund Activity: Q2 2019 in Review

72 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Cytosorbents Corp (CTSO) for Q2 2019, worth a combined $56.3M — down 13% from $64.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CTSO and 8 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 25 added.

The largest buyer was Nuveen, opening a new position worth an estimated $801K. The largest seller was Millennium Management, exiting entirely with an estimated $744K sold.

  • 72 institutional investors held Cytosorbents Corp (CTSO) as of Q2 2019, down from 77 in Q1 2019.
  • Funds reported $56.3M of Cytosorbents Corp stock for Q2 2019, down 13% quarter-over-quarter.
  • 8 funds opened new Cytosorbents Corp positions in Q2 2019 and 10 closed out, a net change of -2 holders.
  • The largest Cytosorbents Corp buyer in Q2 2019 was Nuveen, an estimated $801K added.
  • The largest Cytosorbents Corp seller in Q2 2019 was Millennium Management, an estimated $744K sold.

Based on aggregated 13F filings for Q2 2019.